| Diagnosis: AML, APL, ALL B | 16 (89%), 1 (5.6%), 1 (5.6%) |
| CG/molecular risk: Favorable, Intermediate, Advers | 1 (5.9%), 10 (58.8%), 6 (35.3%) |
| Rescue chemotherapy: FLAG-Ida, Clofarabine-Cytarabine,Fludarabine-Cytarabine, Fludarabine-Carboplatin-Topotecan | 6 (33.3%), 8 (44.4%), 3 (16.7), 1 (5.6%) |
| Sequential conditioning régimen: Melphalan, Fludarabine-Busulfan, Busulfan-Thiotepa, Thiotepa-Fludarabine-Busulfan, Busulfan, TBI | 5 (27.8), 1 (5.6%), 1 (5.6%), 5 (27.8%), 2 (11.1%), 1 (5.6%) |
| Donor type: HLA-id sibling, MUD, MMRD (haplo) | 6 (33.3%), 3 (16.7%), 9 (50%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.